Objective:To analyze a set of prognostic factors for angioimmunoblastic T-cell lymphoma (AITL) and determine whether early progression of disease (POD) is associated with poor prognosis in patients with AITL. Methods: In this study, we enrolled 231 AITL patients from the First Affiliated Hospital of Zhengzhou University and established a clinical risk model specifically for POD 12 by analyzing the effects of clinical variables and POD 12 on prognosis. Results: The median age was 63 years, and 88.3% of the patients were diagnosed at an advanced stage (III/IV). The median follow-up time was 42 months, and the 5-year progression-free survival (PFS) and overall survival (OS) estimates were 11.9% and 26.6%, respectively. POD 12 occurred in 65.4% patients, with 5-year OS estimates of 10.7%.According to the multivariate analysis of POD 12, elevated LDH, ECOG score ≥2, PD-1 negativity and the longest diameter of the involved lymph node > 2 cm were associated with the development of POD 12. We established a new prognostic score (PIP model) combining these factors to define low-, intermediate-, and high-risk subgroups with POD 12 risk rates of 41.5%, 61.5% and 82.5%, respectively, and 5-year OS rates of 36.3%, 21.0% and 18.8%, respectively. Conclusion: POD 12 is a powerful prognostic factor for AITL, and patients with POD 12 have particularly poor outcomes. The new PIP model can prospectively predict the occurrence of POD 12 and the overall prognosis of patients with AITL.

Disclosures

No relevant conflicts of interest to declare.

This content is only available as a PDF.
2024
Sign in via your Institution